{"brief_title": "Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients", "brief_summary": "Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland", "condition": ["Non-Hodgkin's Lymphoma"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Interferon Gamma-1b", "Rituximab"], "description": ["100 or 200 mcg, SQ, 3x per week", "375 mg per square meters, IV, 1x per week"], "criteria": "- Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy - Patients who were on other therapy including CHOP or radiation - Previous therapy must have concluded 30 days prior to enrollment - Demonstrable CD20-positive tumor population in lymph nodes or bone marrow", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "keyword": "lymphoma", "mesh_term": ["Lymphoma", "Lymphoma, Non-Hodgkin", "Rituximab", "Interferons", "Interferon-gamma"], "id": "NCT00057447"}